Simulect Drug Interactions

No metabolic drug-drug interactions are to be expected because Simulect is an immunoglobulin.
In addition to cyclosporin for microemulsion and steroids, other medications have been administered in clinical trials without any incremental adverse reactions in the Simulect group as compared to the placebo group, including systemic antiviral medications (60% Simulect, 66% placebo), systemic antibacterial medications (99% both groups), systemic antimycotic medications (47% Simulect, 42% placebo), analgesics (91% Simulect, 92% placebo), antihypertensive medications eg, β-blocking agents (55% Simulect, 64% placebo) or calcium-channel blockers (91% both groups), diuretics (86% Simulect, 89% placebo).
Other immunosuppressives given in the phase 3 studies included azathioprine, mycophenolate mofetil and antibody preparations. During the first 3 months post-transplantation, 10.5% of Simulect patients and 21.7% of placebo patients in the pooled phase 3 studies received triple therapy including azathioprine or mycophenolate mofetil for at least 1 month, with no increase in adverse events or infections in the Simulect group as compared to the placebo group. During the same period, 14% of patients in the Simulect group and 27% of patients in the placebo group had an acute rejection episode treated with antibody therapy (OKT 3 or ATG/ALG), with no increase adverse events or infections in the Simulect group as compared to placebo.
Human antimurine antibody (HAMA) responses in Simulect-treated patients are rare (3.5%). The use of Simulect does not preclude subsequent treatment with murine antilymphocyte antibody preparations.
Incompatibilities: None known.